Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Allegra-D (fexofenadine) is an over-the-counter oral antihistamine and nasal decongestant for the temporary relief of nasal and sinus congestion due to colds or allergies.
Brand Name : Allegra-D
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 22, 2022
Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : LTL Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
LTL Pharma to Take Over Sanofi’s Diregura in Japan
Details : LTL Pharma will take over the Japanese marketing authorization (MA) of Sanofi’s anti-allergic medicine Diregura (fexofenadine + pseudoephedrine).
Brand Name : Diregura
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2020
Lead Product(s) : Fexofenadine Hydrochloride,Pseudoephedrine
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : LTL Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?